Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 2,491

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

Open access
Richardson, Paul G., Sonneveld, Pieter, Schuster, Michael W., Irwin, David, Stadtmauer, Edward A., Facon, Thierry, Harousseau, Jean-Luc, Ben-Yehuda, Dina, Lonial, Sagar, Goldschmidt, Hartmut, Reece, Donna, San-Miguel, Jesus F., Bladé, Joan, Boccadoro, Mario, Cavenagh, Jamie, Dalton, William S., Boral, Anthony L., Esseltine, Dixie L., Porter, Jane B., Schenkein, David, Anderson, Kenneth C. · 2005 · New England Journal of Medicine

Abstract

BACKGROUND: This study compared bortezomib with high-dose dexamethasone in patients with relapsed multiple myeloma who had received one to three previous therapies. METHODS: We randomly assigned 669 patients with relapsed myeloma to receive either an intravenous bolus of bortezomib (1.3 mg per square meter of body-surface area) on days 1, 4, 8, and 11 for eight three-week cycles, followed by treatment on days 1, 8, 15, and 22 for three five-week cycles, or high-dose dexamethasone (40 mg orally) on days 1 through 4, 9 through 12, and 17 through 20 for four five-week cycles, followed by treatment on days 1 through 4 for five four-week cycles. Patients who were assigned to receive dexamethasone were permitted to cross over to receive bortezomib in a companion study after disease progression. RESULTS: Patients treated with bortezomib had higher response rates, a longer time to progression (the primary end point), and a longer survival than patients treated with dexamethasone. The combined complete and partial response rates were 38 percent for bortezomib and 18 percent for dexamethasone (P<0.001), and the complete response rates were 6 percent and less than 1 percent, respectively (P<0.001). Median times to progression in the bortezomib and dexamethasone groups were 6.22 months (189 days) and 3.49 months (106 days), respectively (hazard ratio, 0.55; P<0.001). The one-year survival rate was 80 percent among patients taking bortezomib and 66 percent among patients taking dexamethasone (P=0.003), and the hazard ratio for overall survival with bortezomib was 0.57 (P=0.001). Grade 3 or 4 adverse events were reported in 75 percent of patients treated with bortezomib and in 60 percent of those treated with dexamethasone. CONCLUSIONS: Bortezomib is superior to high-dose dexamethasone for the treatment of patients with multiple myeloma who have had a relapse after one to three previous therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa043445

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 15

  1. 10.1002/ajh.2830360303 · doi:10.1002/ajh.2830360303
  2. Hideshima T, 2001, Cancer Res, 61, 3071
  3. LeBlanc R, 2002, Cancer Res, 62, 4996
  4. Calhoun EA, 2000, Proc Am Soc Clin Oncol, 19, 446a
  5. Durie BGM, 1999, Blood, 94, 316
  6. Grosbois B, 2001, Blood, 98, 689
  7. Hus M, 2001, Haematologica, 86, 404
  8. Rajkumar SV, 2000, Blood, 96, 168a
  9. Raza SN, 2000, Blood, 96, 168a
  10. Tosi P, 2002, Haematologica, 87, 408
  11. Neben K, 2002, Clin Cancer Res, 8, 3377
  12. 10.1111/j.1365-2141.1992.tb06466.x · doi:10.1111/j.1365-2141.1992.tb06466.x
  13. Niesvizky R, 2003, Proc Am Soc Clin Oncol, 22, 582
  14. Rajkumar SV, 2004, J Clin Oncol, 22, 560s, 10.1200/jco.2004.22.14_suppl.6508 · doi:10.1200/jco.2004.22.14_suppl.6508
  15. Richardson PG, 2003, Blood, 102, 149a

Cited by

See all 2,491

Metadata

Authors
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J. F., Bladé, J., Boccadoro, M., Cavenagh, J., Dalton, W. S., Boral, A. L., Esseltine, D. L., Porter, J. B., Schenkein, D., & Anderson, K. C.
Venue
New England Journal of Medicine
Published
2005-06-16
Volume
352
Issue
24
Pages
2487-2498
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2124560610
Cited by
2,491
References
31
FWCI
100.31
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.